Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
about
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.Endocrine manifestations of systemic mastocytosis in bone.Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
P2860
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@en
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@nl
type
label
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@en
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@nl
prefLabel
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@en
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
@nl
P2093
P2860
P50
P1476
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis
@en
P2093
Gaia Tripi
Massimiliano Bonifacio
Maurizio Rossini
Ombretta Viapiana
Roberta Zanotti
Silvano Adami
P2860
P2888
P304
P356
10.1007/S00223-015-9969-5
P407
P577
2015-02-20T00:00:00Z